Carol didn't start semaglutide to lose weight. She started it because her cardiologist recommended it. She was confused. "Isn't this a diabetes drug? A weight loss drug?" she asked me. "What does it have to do with my heart?"
It's a fair question, and one I get more often than people might expect. The cultural conversation around GLP-1s has narrowed almost entirely to weight loss — the before-and-afters, the appetite suppression, the dress sizes. What's gotten lost is something far more interesting clinically: these medications are reshaping how we think about cardiovascular risk, neurodegeneration, and — with real nuance — certain cancers.
This is the conversation the headlines aren't having. Let's have it properly.
THE HEART: THIS IS WHERE THE EVIDENCE IS STRONGEST
If there's one effect of GLP-1 medications that has moved from "promising" to "established," it's cardiovascular protection.
The landmark SELECT trial confirmed that GLP-1 receptor agonists are suitable for non-diabetic adults with obesity and established cardiovascular disease — not just people with diabetes. That's a significant expansion of who these medications are understood to help.
Large-scale cardiovascular outcome trials have shown substantial reductions in heart attack, stroke, cardiovascular death, and heart failure events. The mechanisms go well beyond blood sugar control: GLP-1 receptors exist directly in cardiovascular tissue, and these medications appear to reduce inflammation, protect the endothelium (the inner lining of blood vessels), and reduce atherosclerotic plaque activity.
A 2025 meta-analysis spanning nearly 100,000 patients reinforced this picture clearly, and the benefit holds even in more complex populations — including people with peripheral artery disease, where GLP-1 use was associated with meaningfully lower all-cause and cardiovascular mortality.
The clinical takeaway: if you have cardiovascular disease, or strong risk factors for it, and you're a candidate for a GLP-1, the conversation with your doctor about these medications is no longer just about weight. It's about your heart, specifically.
THE BRAIN: ENCOURAGING, REAL, AND STILL BEING PROVEN
This is the part of the research that genuinely surprises people.
GLP-1 receptors aren't only in your gut and pancreas — they're in your brain too, including regions tied to memory and cognitive function. This has opened a serious area of research into whether these medications could reduce dementia risk.
Multiple large real-world studies published in 2025 point in the same encouraging direction. One analysis of over 109,000 individuals found GLP-1 use associated with a 26% reduction in dementia incidence. A separate population-based cohort study of patients with type 2 diabetes found similar associations. Cleveland Clinic researchers, publishing in Alzheimer's & Dementia, found comparable signals using large real-world datasets.
The proposed mechanisms are compelling: reduced neuroinflammation, improved blood flow to the brain, protection of the blood-brain barrier, and even enhanced neurogenesis in the hippocampus — the brain's memory center. Animal studies have shown liraglutide reversing cognitive impairment and reducing the abnormal protein buildup associated with Alzheimer's disease.
The honest caveat: this is real-world observational evidence, not yet definitive proof. As Dr. Suzanne Craft, director of the Wake Forest Alzheimer's Disease Research Center, has noted, observational studies carry inherent bias, and the gold standard — randomized controlled trials — are still underway. The pivotal EVOKE trials, studying semaglutide specifically for early Alzheimer's disease, are expected to report results soon. Until then, the research is best described as genuinely promising, not yet conclusive.
CANCER: WHERE THE STORY GETS MORE COMPLICATED — AND MORE IMPORTANT TO GET RIGHT
This is the part of the conversation that requires the most care, because the data doesn't point in one single direction. It depends heavily on which cancer we're discussing.
Colorectal and liver cancer: The most comprehensive analysis to date — a 2026 meta-analysis of 93 randomized controlled trials with over 1.8 million participants — found GLP-1 use associated with meaningfully reduced risk of both colorectal cancer and liver cancer. This makes biological sense: type 2 diabetes and obesity are established risk factors for gastrointestinal cancers, largely through chronic high insulin levels, insulin resistance, and systemic inflammation. By improving those underlying drivers, GLP-1s may be addressing cancer risk at its metabolic root.
Pancreatic cancer: This is the most debated question in the field, and I want to represent it honestly rather than oversimplify in either direction.
The concern originated over a decade ago, when early FDA adverse event data flagged a possible signal for pancreatic cancer with exenatide. That signal prompted an FDA warning and years of follow-up research — and the picture since has been genuinely mixed. Some retrospective database studies have found a modestly elevated risk. Others — including a large 2025 randomized-controlled-trial meta-analysis and a separate study specifically in patients with chronic pancreatitis — found GLP-1 use associated with no increased risk, or even a reduced risk, of pancreatic cancer.
The most likely explanation for this inconsistency: pancreatic cancer risk in people with diabetes is already elevated by the disease itself, which makes it genuinely difficult to separate the medication's effect from the underlying condition it's treating. The 2026 meta-analysis mentioned above — the largest RCT-only synthesis on this question to date — found pancreatic cancer risk was not significantly elevated in GLP-1 users.
What this means practically: the evidence does not currently support pancreatic cancer as an established risk of GLP-1 therapy, but it also hasn't been fully ruled out as a possibility in certain higher-risk patients. If you have a personal or strong family history of pancreatic cancer, or a history of pancreatitis, this is a conversation to have directly with your prescribing physician — not a reason to assume the worst, but a reason to make sure your specific risk profile is part of the decision.
WHY THIS MATTERS BEYOND THE HEADLINES
Here's what I want you to take from all of this: GLP-1 medications were developed for blood sugar control. What's emerged since is a much bigger story about metabolic disease as the common root of cardiovascular disease, neurodegeneration, and several cancers.
Chronic inflammation. Insulin resistance. Visceral fat. These aren't separate problems — they're connected drivers behind conditions that look completely unrelated on the surface. A medication that meaningfully improves the metabolic picture has ripple effects far beyond the number on the scale.
This is also exactly why nutrition matters so much alongside these medications — a theme I keep coming back to in this series. The same anti-inflammatory, fiber-rich, protein-adequate way of eating that supports your results on a GLP-1 is doing parallel work on your cardiovascular system, your brain, and your long-term cancer risk. The medication and the plate are working toward the same goal from two directions.
WHAT TO ACTUALLY DO WITH THIS INFORMATION
If you're on a GLP-1, or considering one, here's the version of this conversation worth having with your care team:
If you have cardiovascular disease or strong risk factors, ask specifically how a GLP-1 might support your cardiovascular health — not just your weight.
If a family history of Alzheimer's or dementia is part of your story, this research may be relevant context, even though it's not yet a clinical indication.
If you have a personal or family history of pancreatic cancer or pancreatitis, raise this directly before starting therapy.
Regardless of any of the above, the nutritional foundation — protein, fiber, anti-inflammatory whole foods — is doing real work for all of these outcomes simultaneously.
The medication is one part of a much larger metabolic story. The rest of that story is written at your table.
Want to talk through your specific health history and how nutrition fits alongside your GLP-1 therapy? That's exactly what I do. Book a consultation today.
References: Kalayci et al., European Heart Journal – Cardiovascular Pharmacotherapy (2025). SELECT Trial, NEJM. Lin et al. and Cheng et al., real-world dementia cohort studies (2025). Zhang et al., Alzheimer's & Dementia (2025). Wali et al., Frontiers in Pharmacology, GI malignancy meta-analysis (2026). Wen et al., Endocrinology, Diabetes & Metabolism, pancreatitis/pancreatic cancer meta-analysis (2025). MDPI Cancers, GLP-1 and pancreatic cancer in chronic pancreatitis (2026).
